The treatment journey of children with moderate to severe atopic dermatitis in Türkiye: unmet needs.
| Autor: | İlgün Gürel D; Department of Pediatric Allergy, Hacettepe University School of Medicine, Ankara, Türkiye., Ünsal H; Department of Pediatric Allergy, Hacettepe University School of Medicine, Ankara, Türkiye., Soyak Aytekin E; Department of Pediatric Allergy, Hacettepe University School of Medicine, Ankara, Türkiye., Soyer Ö; Department of Pediatric Allergy, Hacettepe University School of Medicine, Ankara, Türkiye., Şahiner Ü; Department of Pediatric Allergy, Hacettepe University School of Medicine, Ankara, Türkiye., Ersoy Evans S; Department of Dermatology, Hacettepe University School of Medicine, Ankara, Türkiye., Şekerel BE; Department of Pediatric Allergy, Hacettepe University School of Medicine, Ankara, Türkiye. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The Turkish journal of pediatrics [Turk J Pediatr] 2024 Jul 11; Vol. 66 (3), pp. 265-274. Date of Electronic Publication: 2024 Jul 11. |
| DOI: | 10.24953/turkjpediatr.2024.4569 |
| Abstrakt: | Background: Atopic dermatitis (AD) substantially burdens individuals, families, and healthcare systems. We aimed to document the treatment journey of pediatric patients with moderate-to-severe AD in a referral center based in our country. Methods: This retrospective study reviewed patients aged 1-18 years diagnosed with AD, seeking systemic treatment recommendations from the "pediatric allergy and dermatology multidisciplinary team meeting". Results: Over the 14-month study period, 30 (12.5%) of 240 AD patients were evaluated in the pediatric dermato-allergy team meetings. The median age of the patients was 13.66 years (Q1-Q3: 7.94-17.27), of whom 60% were male. The median annual healthcare visits for AD were 4 (Q1-Q3: 1.00-8.75). Among the study group, 70% were sensitized to aeroallergens, and admission markers included total IgE (median: 1980 IU/mL, Q1-Q3: 794.50-5446), and eosinophil counts (median: 650, Q1-Q3: 275-1275). All patients utilized intermittent and/or continuous topical corticosteroids (CS), with 56.6% employing short-term/long-term topical tacrolimus. Over the past two years, systemic CSs were utilized in 93.3% of the patients, whereas 57.1% received more than one course. Approximately 43.3% of the patients agreed to receive systemic cyclosporine treatment, with only 30.8% benefiting and 3.3% reporting adverse effects (hypertrichosis and cellulitis). Three patients self-funded dupilumab, all benefiting without adverse effects. Omalizumab, mycophenolate mofetil and narrow-band ultraviolet (UV) treatments were used in one patient each, with limited benefit observed. Health insurance did not grant approval for a Janus kinase inhibitor for one patient. Conclusions: Managing moderate to severe AD is complex and costly, considering disease heterogeneity, comorbidities, care pathways, and health system challenges. Addressing the unmet needs should be a priority in Türkiye's healthcare systems. Competing Interests: The authors declare that there is no conflict of interest. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|